Clinical trials: Breast Cancer (Early Breast Cancer)
Breast Cancer
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative…
- Trial name
- ELEGANT (NCT06492616)
- Testing
- Elacestrant, Anastrozole, Letrozole
- Where
- 567 sites in United States, Argentina and 26 more
- Volunteers
- 4,220 people
- Sponsor
- Stemline Therapeutics, Inc.
Breast Neoplasm Female
Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer
This is an Italian, single center, randomized, phase II study. ATRA (all-trans retinoic acid) and derivatives (retinoids) are promising anticancer agents and exert their anti-proliferative, differentiating and apoptotic effects…
- Trial name
- ATRA (NCT04113863)
- Testing
- all-trans retinoic acid, Anastrozole 1mg
- Where
- 2 sites in Italy
- Volunteers
- 76 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Breast Neoplasms
Outcomes Of The Spanish Cohort Of Early Access To Pertuzumab And Trastuzumab Emtansine
The overall study objective is to evaluate the effectiveness and safety of Trastuzumab emtansine (T-DM1) and Pertuzumab under real-world disease conditions in the Spain, and specifically in patients treated under compassionate…
- Trial name
- KNOWHER (NCT03025711)
- Where
- Spain
- Volunteers
- 220 people
- Sponsor
- BELEN RUIZ-ANTORAN
Breast Cancer, Adjuvant Therapy
A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib
The purpose of this study is to describe the demographic and clinical profiles of patients with early-stage HER2+ breast cancer treated with neratinib as an extended adjuvant therapy as part of the Early Access Program (EAP) in…
- Conditions
- Breast Cancer, Adjuvant Therapy, HER2-positive Breast Cancer
- Trial name
- NEAR (NCT05599334)
- Where
- 25 sites in Belgium, Croatia and 3 more
- Volunteers
- 111 people
- Sponsor
- Pierre Fabre Medicament
Breast Cancer (Early Breast Cancer), Postoperative Shoulder Dysfunction
Prehabilitation in Breast Cancer Surgery
This prospective, randomized, assessor-blinded, parallel-group clinical trial evaluates the effectiveness of a home-based upper extremity-focused prehabilitation program in women undergoing breast cancer surgery.
- Conditions
- Breast Cancer (Early Breast Cancer), Postoperative Shoulder Dysfunction, Lymphedema Arm, Cancer Rehabilitation
- Trial name
- NCT07425379
- Testing
- Home-Based Prehabilitation Exercise Program, Usual Care
- Where
- Turkey (Türkiye)
- Volunteers
- 54 people
- Sponsor
- Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Breast Cancer
TAC Versus TC for Adjuvant Breast Cancer
The purpose of this research study is to find out what effects (good and bad) TC or TAC has on early stage HER2- breast cancer.
- Trial name
- NCT00493870
- Testing
- Docetaxel, Doxorubicin, Cyclophosphamide
- Where
- 95 sites in United States
- Volunteers
- 1,961 people
- Sponsor
- US Oncology Research
Breast Cancer
Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer
Investigators propose to study the efficacy of Bevacizumab plus systemic chemotherapy prior to surgery in order to make a locally advanced tumor operable.
- Trial name
- NCT01985841
- Testing
- Bevacizumb, 5-Fluorouracil, Epirubicin
- Where
- 6 sites in Greece
- Volunteers
- 34 people
- Sponsor
- Hellenic Oncology Research Group
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
ON-treatment Single-cell Analysis for the Identification of Early Tumor Response Biomarkers on Prospective Collected Serial Tumor Biopsies in Triple Negative Breast Cancer Patient During Standard Neoadjuvant Chemo-immunotherapy
This study explores early breast cancer, focusing on triple-negative and high-risk luminal subtypes. It combines single-cell RNA sequencing and spatial imaging of tumor samples collected at different time points during treatment.
- Trial name
- ONSET (NCT07597642)
- Testing
- on treatment biopsy (after C1)
- Where
- Italy
- Volunteers
- 55 people
- Sponsor
- IRCCS San Raffaele
Early Stage Breast Carcinoma
Registry of Patients Undergoing Cryoablation for Early Stage Breast Cancer
This study evaluates the side effects and outcomes of patients who undergo cryoablation for early stage breast cancer.
- Trial name
- NCT06387173
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Breast Cancer
Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer
This is a pilot "window of opportunity" clinical study in patients with operable breast cancer investigating use of reparixin as single agent in the time period between clinical diagnosis and surgery.
- Trial name
- NCT01861054
- Testing
- Reparixin
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dompé Farmaceutici S.p.A
Triple Negative Breast Cancer, Surveillance
Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid Biopsy and Imaging
Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer, often with poor outcomes. Currently, follow-up for TNBC consists of physical exams and annual breast imaging, with additional scans only if symptoms…
- Conditions
- Triple Negative Breast Cancer, Surveillance, Recurrence, ctDNA
- Trial name
- EINSTEIN-TNBC (NCT07478705)
- Testing
- ctDNA-guided imaging surveillance, Standard
- Volunteers
- 30 people
- Sponsor
- Sunnybrook Health Sciences Centre
Breast Neoplasms
Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
This randomized, open-label, crossover study will evaluate participants' preference and healthcare professional (HCP) satisfaction with SC versus IV Herceptin administration in HER2-positive early breast cancer.
- Trial name
- PrefHER (NCT01401166)
- Testing
- Herceptin, Single-Use Injection Device
- Where
- 75 sites in Canada, Denmark and 10 more
- Volunteers
- 488 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer Invasive
Ultrasound Imaging, Spectroscopy and Ultrasound Imaging of Vascular Blood Flow as Early Indicators of Breast Cancer Response to Neoadjuvant Treatment.
We have previously demonstrated that high-frequency ultrasound and spectroscopy, and recently conventional-frequency ultrasound and spectroscopy may be used to detect cell death in vitro, in situ and in vivo.
- Trial name
- NCT00437879
- Where
- Canada
- Volunteers
- 600 people
- Sponsor
- Sunnybrook Health Sciences Centre
Breast Cancer (Early Breast Cancer)
Skipping Hormone Therapy in Low-Risk Early Breast Cancer
The goal of this clinical trial is to determine whether a selected population of women with early-stage, low-risk breast cancer can avoid hormone therapy without increasing their risk of relapse.
- Trial name
- NoELA (NCT07661927)
- Testing
- Removing Endocrine Therapy
- Where
- 41 sites in France
- Volunteers
- 700 people
- Sponsor
- UNICANCER
Breast Cancer
Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy
The activity of trastuzumab in early-stage, HER2-positive breast cancer, has been demonstrated in many studies, with meta-analyses showing that in combination with a variety of chemotherapy backbones, trastuzumab reduces the risk…
- Trial name
- NCT04928261
- Testing
- Trastuzumab
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- Ottawa Hospital Research Institute
Low-Risk, Early Stage Breast Cancer
Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial)
The FDA has granted marketing authorization for the ProSense® Cryoablation System for the local treatment of patients aged 70 years or older with low-risk early-stage breast cancer who are also receiving adjuvant hormone therapy.
- Trial name
- NCT07629206
- Testing
- Cryoablation
- Where
- 3 sites in United States
- Volunteers
- 400 people
- Sponsor
- IceCure Medical Ltd.
Breast Cancer
Promoting Early Detection of Breast Cancer in Rural Rwanda: Impact of Community Health Worker and Nurse Training
This project proposes a pilot intervention in Burera District to train rural Rwandan community health workers (CHWs) in breast awareness, and to train primary care nurses at rural health centers in the assessment and management…
- Trial name
- BCED (NCT03919682)
- Testing
- Experimental: Training, Phase 1, Experimental: Training, Phase 2
- Volunteers
- 1,203 people
- Sponsor
- Brigham and Women's Hospital
Radiation Injury, Breast Cancer
Breast Cancer Lung Late Effects
Through improved early detection and treatment, the number of long term breast cancer survivors continues to increase. There are now 2.8 million breast cancer survivors in the U.S.
- Trial name
- BELLE (NCT02725840)
- Testing
- Proton beam radiation therapy., X-ray based radiation therapy, Computed Tomography (CT) Scan
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- University of Florida
HER2-positive Breast Cancer
Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer
Human epidermal growth factor receptor 2 (HER2) positive breast cancer is a molecular subtype with high malignancy and high risk to recurrence and metastasis.
- Trial name
- NeraHER2 (NCT06693024)
- Testing
- neratinib
- Where
- China
- Volunteers
- 2,806 people
- Sponsor
- Shu Wang
Breast Cancer, Gynecologic Cancer
Evaluation of Hydroxychloroquine to Prevent CIPN
The study is being done to research if hydroxychloroquine can prevent chemotherapy induced peripheral neuropathy. Certain chemotherapy drugs, like paclitaxel, are known to cause neuropathy which can impact quality of life.
- Conditions
- Breast Cancer, Gynecologic Cancer, Early-stage Breast Cancer, Peripheral Neuropathy
- Trial name
- NCT05689359
- Testing
- Hydroxychloroquine
- Sponsor
- University of Arizona
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.